Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a dismal
prognosis. The lack of symptoms in the early phase of the disease makes early diagnosis …

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC),
contributing to early metastasis and poor patient survival. Compared to the localized tumors …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Background In patients undergoing resection for pancreatic cancer, adjuvant modified
fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival …

Recently, a strong correlation between metabolic disorders, tumor onset, and progression
has been demonstrated, directing new therapeutic strategies on metabolic targets. OLR1 …

Pancreatic cancer is a malignant disease with high mortality and poor prognosis due to lack
of early diagnosis and low treatment efficiency after diagnosis. Although Gemcitabine (GEM) …

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide and is
predicted to become second in 2030 in industrialized countries if no therapeutic progress is …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death
worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a …

Simple Summary This review takes the extracellular matrix (ECM) as the starting point, and
describes its influence and related mechanisms on the biological behavior of pancreatic …

Pancreatic adenocarcinoma (PAAD) is a common, highly malignant, and aggressive
gastrointestinal tumor. The conventional treatment of PAAD shows poor results, and patients …